These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29896099)

  • 1. Evaluation of RNA Blood Biomarkers in the Parkinson's Disease Biomarkers Program.
    Santiago JA; Bottero V; Potashkin JA
    Front Aging Neurosci; 2018; 10():157. PubMed ID: 29896099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
    Santiago JA; Potashkin JA
    PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
    Bottero V; Santiago JA; Potashkin JA
    J Parkinsons Dis; 2018; 8(4):529-537. PubMed ID: 30248063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A network approach to diagnostic biomarkers in progressive supranuclear palsy.
    Santiago JA; Potashkin JA
    Mov Disord; 2014 Apr; 29(4):550-5. PubMed ID: 24347522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
    J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy.
    Seki M; Seppi K; Mueller C; Potrusil T; Goebel G; Reiter E; Nocker M; Steiger R; Wildauer M; Gizewski ER; Wenning GK; Poewe W; Scherfler C
    Parkinsonism Relat Disord; 2018 Apr; 49():81-87. PubMed ID: 29463454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.
    Fiorenzato E; Antonini A; Camparini V; Weis L; Semenza C; Biundo R
    J Neural Transm (Vienna); 2019 Nov; 126(11):1437-1445. PubMed ID: 31432258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers.
    Vasilevskaya A; Taghdiri F; Multani N; Anor C; Misquitta K; Houle S; Burke C; Tang-Wai D; Lang AE; Fox S; Slow E; Rusjan P; Tartaglia MC
    Front Neurol; 2020; 11():574. PubMed ID: 32754109
    [No Abstract]   [Full Text] [Related]  

  • 10. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease.
    Paslawski W; Khosousi S; Hertz E; Markaki I; Boxer A; Svenningsson P
    Transl Neurodegener; 2023 Sep; 12(1):42. PubMed ID: 37667404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.
    Ondo W; Warrior D; Overby A; Calmes J; Hendersen N; Olson S; Jankovic J
    Arch Neurol; 2000 Oct; 57(10):1464-9. PubMed ID: 11030799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Salvatore C; Cerasa A; Castiglioni I; Gallivanone F; Augimeri A; Lopez M; Arabia G; Morelli M; Gilardi MC; Quattrone A
    J Neurosci Methods; 2014 Jan; 222():230-7. PubMed ID: 24286700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pattern of verbal, visuospatial and procedural learning in Richardson variant of progressive supranuclear palsy in comparison to Parkinson's disease.
    Sitek EJ; Wieczorek D; Konkel A; Dąbrowska M; Sławek J
    Psychiatr Pol; 2017 Aug; 51(4):647-659. PubMed ID: 28987055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Santangelo G; Cuoco S; Pellecchia MT; Erro R; Barone P; Picillo M
    J Neurol; 2018 Nov; 265(11):2602-2613. PubMed ID: 30178175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A
    Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease.
    Pellicano C; Assogna F; Cellupica N; Piras F; Pierantozzi M; Stefani A; Cerroni R; Mercuri B; Caltagirone C; Pontieri FE; Spalletta G
    Parkinsonism Relat Disord; 2017 Dec; 45():50-56. PubMed ID: 29037499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
    Rusz J; Bonnet C; Klempíř J; Tykalová T; Baborová E; Novotný M; Rulseh A; Růžička E
    J Neurol; 2015; 262(4):992-1001. PubMed ID: 25683763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology.
    Rigby HB; Dugger BN; Hentz JG; Adler CH; Beach TG; Shill HA; Driver-Dunckley E; Sabbagh MN; Sue LI; Caviness JN
    Mov Disord Clin Pract; 2015 Mar; 2(1):33-38. PubMed ID: 30363831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.